ETFRank
Markets›United States›Stocks›Healthcare›Drug Manufacturers - General›MRK
MRK

Merck & Co., Inc.

MRK·NYSE
120.79USD+0.53 +0.44%
Alla chiusura del 2026-06-05
PanoramicaGraficoFinanzaEarningsPrevisioni
Market Cap$298.91B
Revenue (FY)$65.01B
Net Income$18.26B
Net Margin+28.1%
EPS (FY)$7.28
P/E (FY)16.6
Shares Out.2.47B
Volume16.0M
SectorHealthcare
52W Range$77 – $125
52W Low$76.66
52W High$125.14
Open$120.94
Prev. Close$120.26
ExchangeNYSE
CurrencyUSD
IndustryDrug Manufacturers - General
CountryUnited States

About Merck & Co., Inc.

Merck & Co., Inc. operates as a leading healthcare company worldwide, specializing in the research, development, and commercialization of innovative pharmaceutical products and vaccines. Its portfolio features prominent human health pharmaceuticals such as Keytruda for oncology treatments, Welireg for specific cancer therapies, and Gardasil for HPV prevention. The company also provides a robust lineup of vaccines including ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, and Pneumovax 23, addressing infectious diseases across age groups. Additional offerings include Bridion for surgical care. Merck & Co., Inc. focuses on key therapeutic areas like oncology, vaccines, hospital acute care, and immunology, serving patients, healthcare providers, and global health systems. Through its operations, the company plays a vital role in advancing treatments for serious diseases and preventive health measures. Founded in 1891 and headquartered in Rahway, New Jersey, Merck & Co., Inc. maintains a strong presence in the biopharmaceutical sector, contributing to global health solutions.

CEO: Mr. Robert M. Davis J.D.Employees: 73,000HQ: Rahway, NJ, United Stateswww.merck.com

Financials

RevenueNet Income
Metric202020212022202320242025
Revenue$41.52B$48.70B$59.28B$60.12B$64.17B$65.01B
Gross Profit$27.90B$35.08B$41.87B$43.99B$48.98B$48.63B
Operating Income$5.55B$13.20B$18.28B$2.95B$20.22B$22.11B
EBITDA$9.56B$16.92B$23.31B$7.54B$26.23B$29.11B
Net Income$7.07B$13.06B$14.53B$377.0M$17.13B$18.26B
EPS (diluted)$2.78$5.14$5.71$0.14$6.74$7.28
Shares (dil.)2.53B2.53B2.53B2.61B2.53B2.47B

Earnings History

DateEPS EstimateEPS ActualSurprise
2026-10-28———
2026-08-03———
2026-04-30$-1.47$-1.28-12.93%
2026-02-16$-10.85$-0.59-94.56%
2026-02-03$2.01$2.04+1.49%
2025-10-30$2.35$2.58+9.79%
2025-07-29$2.03$2.13+4.93%
2025-04-24$2.14$2.22+3.74%
2025-02-04$1.67$1.72+2.99%
2024-10-31$1.57$1.57+0.00%
2024-07-30$2.14$2.28+6.54%
2024-04-25$1.92$2.07+7.81%
2024-02-01$-0.11$0.03-127.27%
2023-10-26$1.95$2.13+9.23%
2023-08-01$-2.18$-2.06-5.50%
2023-04-27$1.34$1.40+4.48%
Market & fundamental data provided by Twelve Data.